NovoCure (NASDAQ:NVCR) Bolsa

NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Ltd

Barclays analyst Lauren Lieberman maintains Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Overweight and lowers the price target from $51 to $40.

News

Price Target

Analyst Ratings

BF/B

Barclays Maintains Overweight on Brown-Forman, Lowers Price Target to $40

No-fault laws are one of the contributing factors to why car insurance premiums climb higher in some states. Twelve states hold these rules and demand that your insurance covers your injuries after a crash despite who caused it.
What are no-fault laws? In a typical setup, the at-fault driver's insurance picks up the tab for your damages, but in no-fault states your own policy steps in to handle your injuries, regardless of blame. This hinges on Personal Injury Protection—PIP for short—a required coverage in these states. PIP takes care of costs tied to the accident including medical bills and lost wages. States like Florida, Michigan, and New York follow this system though each have their own set of rules regarding PIP and subsequent lawsuits.
Here's a twist: no-fault states often block lawsuits for pain and suffering unless injuries hit a serious mark—like severe harm or death. The goal? Fewer court battles and, ideally, lower premiums. But does this actually work out the way it is supposed to?
Supporters say no-fault laws smooth out the claims process because your insurer pays your PIP claim directly. This supposedly cuts delays and legal tangles. Fewer lawsuits over pain and suffering could trim administrative costs for insurance companies and if those savings stack up, they might show up as lower premiums, especially where lawsuit limits hold firm.
But there's a flip side. PIP coverage often costs more than optional medical payments in fault-based states. With its wide reach—covering medical expenses, lost income, and beyond—insurers face bigger payouts. Michigan once had unlimited medical benefits under PIP, sending premiums through the roof. Recent changes let drivers pick lower limits.
Fraud adds another layer to the insurance mess. In Florida and New York, staged crashes and padded claims have jacked up PIP expenses and insurers hit with these losses hike premiums to balance the books. Additionally every injured driver in a no-fault state files a claim with their own company, boosting claim numbers compared to fault-based systems. In at fault states, the number of claims files is half as it is usually only the at fault person filing.
As we&#8217;ve mentioned, insurance premiums depend heavily on where you live. High PIP limits, like Michigan's old standard, tend to mean pricier rates. Strict lawsuit caps can often hold costs down. Fraud also continues to be a huge issue and states that are able tackle fraud effectively can keep steady premiums.
Take Florida for example. Despite aims to curb litigation, fraud and lawsuits have pushed premiums far above the national average. Michigan's recent PIP adjustments hint that scaling back coverage can lighten the load. Other factors—accident frequency, medical costs, and city density—muddy the picture further.
If you live in a no-fault state it might be a good idea to check your PIP minimums to weigh if the extra coverage makes sense. Know your state's lawsuit threshold—it sets the bar for chasing damages beyond PIP. Adding uninsured or underinsured motorist coverage can shield you from drivers with skimpy policies, though PIP steps in either way.
Solid liability coverage matters in fault based states. If you cause a wreck, you'll cover the other side's damages. Optional medical payments coverage can act like PIP, but it often caps out lower.
In conclusion, are no-fault laws a true contributor to inflating premiums? It's a mixed bag. They can streamline claims and trim lawsuits and possibly cut costs. Mandatory PIP and fraud risks can nudge rates up. The real impact depends on your state's rules and broader trends. Understand your local setup and pick a policy that fits—your budget will feel the difference.

Legal

Personal Finance

Insurance

General

Do No-Fault Laws Drive Up Your Car Insurance Premiums?

Barclays analyst Gena Wang maintains Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and lowers the price target from $63 to $57.

Barclays Maintains Overweight on Avidity Biosciences, Lowers Price Target to $57

BLK UP OVER 30 POINTS AFTER THE ALERT
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/28211810/Screenshot-2025-02-28-at-4.08.23%E2%80%AFPM-1024x997.png" alt="" class="wp-image-6946" /></figure>
Today, BlackRock, Inc. (BLK) experienced a power inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
Today, at 11:26 AM on February 28th, a significant trading signal occurred for BlackRock, Inc. (BLK) as it demonstrated a Power Inflow at a price of $948.95. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in BlackRock&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in BlackRock&#8217;s stock price, interpreting this event as a bullish sign.
Signal description Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted by active traders as a bullish signal.
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BLK Benzinga Pro gives you real-time options trades alerts.
Market News and Data brought to you by Benzinga APIs and include firms, like <a href="https://www.tradepulse.net" title="https://www.tradepulse.net">https://www.tradepulse.net</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $948.95. The returns on the High price ($980.43) and Close price ($977.76) after the Power Inflow were respectively 3.3% and 3.0%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close, but that is not always the case
Past Performance is Not Indicative of Future Results

Equities

Technicals

Signals

BlackRock Stock up Over 3% After This Trading Signal

Barclays analyst Saket Kalia maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Overweight and raises the price target from $355 to $365.

ADSK

Barclays Maintains Overweight on Autodesk, Raises Price Target to $365

Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $78.5, a high estimate of $85.00, and a low estimate of $70.00. Observing a 3.29% increase, the current average has risen from the previous average price target of $76.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740780073_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Solventum by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Solventum. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Solventum compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Solventum's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Solventum's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SOLV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Solventum analyst ratings.</a>
<h2>Delving into Solventum's Background</h2>
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
<h3>Unraveling the Financial Story of Solventum</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Solventum showcased positive performance, achieving a revenue growth rate of 0.39% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Solventum's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Solventum's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.03% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Solventum's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.83%, the company showcases efficient use of assets and strong financial health.
Debt Management: Solventum's debt-to-equity ratio stands notably higher than the industry average, reaching 2.54. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SOLV

What Analysts Are Saying About Solventum Stock

During the last three months, 11 analysts shared their evaluations of First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $23.64, with a high estimate of $25.00 and a low estimate of $21.00. Marking an increase of 7.02%, the current average surpasses the previous average price target of $22.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1740780064_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive First Horizon is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.50</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brady Gailey</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$19.50</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to First Horizon. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Horizon compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of First Horizon's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of First Horizon's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FHN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Horizon analyst ratings.</a>
<h2>Delving into First Horizon's Background</h2>
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.
<h3>Understanding the Numbers: First Horizon's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Challenges: First Horizon's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -8.98%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: First Horizon's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 21.64%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): First Horizon's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 1.86%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): First Horizon's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.19%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: First Horizon's debt-to-equity ratio is below the industry average. With a ratio of 0.27, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

11 Analysts Have This To Say About First Horizon

13 analysts have shared their evaluations of Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Prudential Financial and provided 12-month price targets. The average target is $124.85, accompanied by a high estimate of $152.00 and a low estimate of $101.00. This current average has decreased by 1.69% from the previous average price target of $127.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740780058_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Prudential Financial is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$128.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$125.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$134.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$128.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Underperform</td>
<td>$101.00</td>
<td>-</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$127.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$129.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$127.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$117.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$129.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$149.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Prudential Financial. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prudential Financial compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Prudential Financial's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Prudential Financial analyst ratings.</a>
<h2>Delving into Prudential Financial's Background</h2>
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset-management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 10% of its earnings and has around $1.3 trillion in assets under management. The US businesses are responsible for about 50% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
<h3>Unraveling the Financial Story of Prudential Financial</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Prudential Financial's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -17.24%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Prudential Financial's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.44%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.19%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.01%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Prudential Financial's debt-to-equity ratio stands notably higher than the industry average, reaching 0.77. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Prudential Financial Through The Eyes Of 13 Analysts

MetLife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $96.5, a high estimate of $109.00, and a low estimate of $88.00. This current average reflects an increase of 2.66% from the previous average price target of $94.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740780050_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of MetLife by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$98.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$97.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MetLife. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MetLife compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for MetLife's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MetLife's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MET/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MetLife analyst ratings.</a>
<h2>All You Need to Know About MetLife</h2>
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.
<h3>Key Indicators: MetLife's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3 months period, MetLife faced challenges, resulting in a decline of approximately -3.43% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MetLife's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 6.74%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): MetLife's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.25%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): MetLife's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.18%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: MetLife's debt-to-equity ratio stands notably higher than the industry average, reaching 0.68. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On MetLife Through 8 Analysts

Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $9.33, along with a high estimate of $13.00 and a low estimate of $7.00. Highlighting a 13.61% decrease, the current average has fallen from the previous average price target of $10.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1740780039_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Array Technologies among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Rusch</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Maheep Mandloi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Moses Sutton</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Neutral</td>
<td>$9.00</td>
<td>-</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Michael Blum</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Array Technologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Array Technologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Array Technologies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ARRY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Array Technologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Array Technologies</h2>
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers referred to as a single-axis tracker that move solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Its operations are in the United States, Australia, Spain, Brazil and Rest of the World with the United States deriving the majority of the revenue.
<h3>Array Technologies: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Array Technologies's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -33.97%. This indicates a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Array Technologies's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -67.17%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Array Technologies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -117.55%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Array Technologies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.67%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Array Technologies's debt-to-equity ratio surpasses industry norms, standing at 10.49. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARRY

Array Technologies Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

In the preceding three months, 6 analysts have released ratings for Payoneer Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Payoneer Global and provided 12-month price targets. The average target is $12.17, accompanied by a high estimate of $14.00 and a low estimate of $10.00. Marking an increase of 7.7%, the current average surpasses the previous average price target of $11.30. 
<img src="https://www.benzinga.com/files/images/story/2025/1740780021_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Payoneer Global among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Nate Svensson</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Ashwin Shirvaikar</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$8.50</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mike Grondahl</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Payoneer Global. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Payoneer Global compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Payoneer Global's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Payoneer Global's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PAYO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Payoneer Global analyst ratings.</a>
<h2>Unveiling the Story Behind Payoneer Global</h2>
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started to empower global commerce by connecting businesses, professionals, countries, and currencies with its diversified cross-border payments platform.
<h3>Understanding the Numbers: Payoneer Global's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Payoneer Global's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 19.34%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Payoneer Global's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 16.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Payoneer Global's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 5.95%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.6%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Payoneer Global's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAYO

Demystifying Payoneer Global: Insights From 6 Analyst Reviews

Barclays analyst Gena Wang maintains Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Overweight and raises the price target from $26 to $31.

Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $31

Offerings

SYNX

Silynxcom Files For Stock Shelf Of Up To $50M

Cross Country Healthcare, Inc. ("Cross Country" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) today announced that the Company has obtained all requisite stockholder approvals in connection with its proposed acquisition by Aya Healthcare.
As previously disclosed, Cross Country and Aya Healthcare expect to complete the transaction in the second half of 2025, subject to the satisfaction or waiver of customary closing conditions specified in the Merger Agreement. Upon completion of the transaction, Cross Country will become a private company and its common stock will no longer trade on the NASDAQ.

CCRN

Cross Country Healthcare Stockholders Approve Aya Healthcare Transaction

Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) stock is down more than 13% since the end of January and has now <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44048486/bitcoins-24-correction-mostly-technical-say-experts">entered oversold territory.&nbsp;</a>
What To Know: Alphabet's relative strength index fell to 29.17 on Thursday, its lowest since September 2024. The stock's RSI rebounded slightly on Friday to 29.51 at the time of publication, but remains below the 30 level traditionally used to mark a stock as "oversold."&nbsp;
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/44051518/nvidia-tesla-lead-tech-stock-rebound-whats-driving-markets-friday">Nvidia, Tesla Lead Tech Stock Rebound: What&#8217;s Driving Markets Friday?</a>
The company faces multiple headwinds that may have sent investors running for the exit. Here's a look at some of Alphabet&#8217;s recent challenges:&nbsp;
Q4 Revenue Miss: Alphabet&#8217;s fourth-quarter earnings report released Feb.4 showed a slight miss in revenue, particularly in its cloud division. The shortfall, in a key growth area, raised concerns among investors and the stock dropped about 7% the next day. 
Regulatory Pressures: Alphabet faces several<a href="https://www.benzinga.com/news/legal/25/02/43930715/google-sued-over-ai-search-overviews-education-company-says-tech-giant-is-stealing-content-and-driving-publishers-out-of-business"> legal challenges</a>, including an ongoing antitrust case with the Department of Justice that is expected to be settled in mid-2025 and could result in the divestiture of key business segments, including Chrome and Android.
Additionally, China announced an antitrust probe into Alphabet in early February and the company is under investigation by the European Commission for potential violations of its Digital Markets Act.&nbsp;
AI Competition: Google faces potential threats to its search dominance from emerging AI technologies like OpenAI and DeepSeek. The company has<a href="https://www.benzinga.com/markets/equities/25/02/44031714/google-implements-layoffs-in-hr-and-cloud-divisions-as-ai-investment-accelerates-report"> initiated rounds</a> of layoffs in order to reallocate spending toward AI research and development.  
Alphabet also announced a significant increase in capital expenditure from $58 billion to $75 billion for the current year, much of which is AI-focused.&nbsp;
Time To Buy?&nbsp;
Some analysts view Alphabet's current oversold status as a buying opportunity given the stock has a strong balance sheet and is trading at a lower multiple compared to other Big Tech names.&nbsp;&nbsp;
The three most recent analyst ratings have an average price target of $226.67 between them, with an implied 31.74% upside for Alphabet shares. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/02/44007082/q4-gdp-holds-at-2-3-after-minor-revision-in-second-estimate">Q4 GDP Holds At 2.3% After Minor Revision In Second Estimate&nbsp;</a></li>
</ul>
Image: Shutterstock

Large Cap

Movers

Tech

GOOG

GOOGL

Alphabet Stock Enters Oversold Territory — Is It A Buying Opportunity?

Barclays analyst Brandt Montour maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Overweight and lowers the price target from $116 to $97.

Barclays Maintains Overweight on Marriott Vacations, Lowers Price Target to $97

Middlesex Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.36 by 36.11 percent. This is a 53.12 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $47.107 million which beat the analyst consensus estimate of $43.000 million by 9.55 percent. This is a 22.03 percent increase over sales of $38.602 million the same period last year.

Earnings

MSEX

Middlesex Water Q4 2024 GAAP EPS $0.49 Beats $0.36 Estimate, Sales $47.107M Beat $43.000M Estimate

MSGM

Motorsport Games Says On Feb 26, U.S. District Court For District Of Delaware Granted Summary Judgment Motion Filed By Co And Other Defendants; Court Rules In Favor Of Motorsport Games On All Counts

Barclays analyst Raimo Lenschow maintains Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) with a Equal-Weight and lowers the price target from $17 to $16.

JAMF

Barclays Maintains Equal-Weight on Jamf Holding, Lowers Price Target to $16

RVTY

Revvity Files For Mixed Shelf Offering; Size Not Disclosed

Press Releases

Novocure Reports Third Quarter 2024 Financial Results

Novocure Appoints Christoph Brackmann as Chief Financial Officer

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure to Participate in Upcoming Investor Conferences

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Comments

NovoCure

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL